In breast cancer patients, Yamauchi et al. reported that the interaction of E-cad and KLRG1 inhibits antibody-dependent cell-mediated cytotoxicity (ADCC), rendering human epidermal growth factor receptor-2-expressing tumor cells resistant to trastuzumab treatment. Here, CDH1 is linked to breast cancer.